Product Description
Calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a drug commonly used in the treatment of diabetic retinopathy and chronic venous insufficiency. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9703201/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Bangladesh | Bosnia | Brazil | Bulgaria | Chile | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Italy | Jordan | Korea | Lebanon | Malaysia | Malta | Mexico | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Arab Emirates | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Wangao Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Switzerland
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COVID-19 | P2 |
Completed |
COVID-19 |
2023-11-10 |